Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2)
Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)
Sponsor: Celcuity Inc
Listed as NCT03812393, this PHASE2 trial focuses on Early-stage Breast Cancer and HER2-positive Breast Cancer and remains ongoing. Sponsored by Celcuity Inc, it has been updated 10 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
May 2023 — Jan 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Oct 2021 — May 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2019 — Nov 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celcuity Inc
- Puma Biotechnology, Inc.
- West Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .